49Y Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avenue Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.08 |
| 52 Week High | US$44.63 |
| 52 Week Low | US$1.98 |
| Beta | -0.18 |
| 11 Month Change | -16.13% |
| 3 Month Change | -32.03% |
| 1 Year Change | -95.34% |
| 33 Year Change | -99.84% |
| 5 Year Change | n/a |
| Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 49Y | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -1.0% |
| 1Y | -95.3% | -11.6% | 12.8% |
Return vs Industry: 49Y underperformed the German Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: 49Y underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| 49Y volatility | |
|---|---|
| 49Y Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 49Y's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 49Y's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Alix MacLean | www.avenuetx.com |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Avenue Therapeutics, Inc. Fundamentals Summary
| 49Y fundamental statistics | |
|---|---|
| Market cap | €3.03m |
| Earnings (TTM) | -€13.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 49Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 49Y income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.68m |
| Earnings | -US$14.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 49Y perform over the long term?
See historical performance and comparison